Background
==========

Nasopharyngeal carcinoma (NPC) is unique in terms of epidemiology, pathogenesis, and physical history compared to the anatomically adjacent cancers of the head and neck area. Approaching nasopharyngeal cancer as a single entity is misleading, since it is comprised of separate histology subtypes characterized by variable radio- and chemo-sensitivity, distinct prevalence patterns and different outcome \[[@B1]\]. Particularly, the nonkeratinizing undifferentiated subtype (WHO III) is endemic in southern China and common in Asian and African regions; Epstein-Barr virus (EBV) is implicated as the causal agent in the vast majority of these cases, characterized by a favorable prognosis. On the contrary, the keratinizing and the nonkeratinizing differentiated variants (WHO I and II, respectively) account together for 50%--75% of NPCs in the United States \[[@B2]\].

Evolution of personalized medicine is widely acknowledged as the only way to overcome the inherent limitations of chemotherapy \[[@B3]\]. As a matter of fact, research on the development of prognostic and predictive markers in head and neck squamous cell carcinomas (HNSCC) has led to the incorporation of cetuximab, an anti-EGFR monoclonal antibody, into the contemporary therapeutic management. However, these advances are not applicable to NPC arena, for which translational research has not yielded remarkable outcomes yet. As a result, NPC is still managed as a homogeneous disease and the prognosis of patients diagnosed in advanced stage remains poor \[[@B4]\]. Notably, the main bulk of research efforts originate from the Far East, thus questioning the potential application of any findings to NPC patients of Caucasian origin.

Building upon these prerequisites, our group performed a comprehensive, mostly immunohistochemical (IHC), expression profiling of 21 biomolecules from tumors of locally advanced NPC (LA-NPC) Caucasian patients treated with chemotherapy or chemo-radiotherapy (CRT) in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized trial \[[@B5]\]. Biomolecules were selected on the basis of a wide representation of signaling pathways and processes critical in driving carcinogenesis, such as angiogenesis, cell adhesion, assembly, proliferation and differentiation, cell cycle and transcription regulation, DNA repair, microtubule assembly, and inflammation mediation.

To the best of our knowledge, this is the first report of such a broad protein expression profiling in a considerable number of Caucasian NPC patients.

Methods
=======

The clinical study -- ethics approval
-------------------------------------

This is a translational study in LA-NPC patients performed as an extension of a randomized trial, conducted by HeCOG \[[@B5]\], which tested the addition of induction chemotherapy (cisplatin 75 mg/m^2^, epirubicin 75 mg/m^2^ and paclitaxel 175 mg/m^2^ every 3 weeks) (patient Group A) to the standard approach of concurrent chemo-radiotherapy with cisplatin (patient Group B). The main eligibility criteria were as follows: (i) biopsy-proven, previously untreated WHO type I, II or III NPC; (ii) age \>15 years; (iii) stage II--IVB according to the American Joint Committee on Staging of Cancer classification (AJCC 7th edition, 2009); (iv) measurable or evaluable disease; (v) no other primary tumors; (vi) performance status (PS) of 0--2 according to the Eastern Cooperative Oncology Group (ECOG) scale.

Tissue paraffin blocks and peripheral blood for DNA analysis were prospectively collected from each patient registered in the study. The clinical protocol and collateral translational research studies were approved by the HeCOG Protocol Review Committee, the Institutional Review Boards in participating institutions and the Bioethics Committee of the Aristotle University of Thessaloniki School of Medicine under the general title: "Investigation of putative predictive or prognostic biomarkers in patients with locally advanced nasopharyngeal carcinoma". The study was also registered at the Australian New Zealand registry (ACTRN 12609000730202). Prior to randomization each patient provided a study-specific written informed consent and optionally a separate informed consent for the provision of biological material for future research studies.

Tissue samples for molecular analysis
-------------------------------------

One hundred and nineteen formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 118 patients were available for analysis (only in one case, 2 samples were examined from 1 patient). Eleven blocks were not further evaluated due to inappropriate material (inadequate material in 7 cases and no tumor in 4 cases). Thus, 108 samples from 107 patients were examined for EBV-related small RNA (EBER) detection with the use of chromogenic *in situ* hybridization (CISH) \[[@B6]\] and for a number of key regulatory proteins by utilizing IHC \[[@B7],[@B8]\]. Finally, 105 samples from 105 patients were successfully assessed with CISH and IHC (REMARK diagram, Figure [1](#F1){ref-type="fig"}). Representative slides (hematoxylin and eosin, H&E) from the tissue blocks were reviewed by an experienced pathologist (M.B.) for confirmation of the diagnosis and adequacy of material as well as calculation of the percentage of tumor cells in each case. In 97 cases, the tumor tissue in the paraffin block was adequate for the construction of tissue microarrays (TMA), while for 11 cases all assays were performed on whole tissue sections.

![REMARK diagram of the study.](1472-6890-13-1-1){#F1}

TMA construction
----------------

Tumor tissue specimens were arrayed (3 cores per case, 0.6 mm in diameter) into a recipient paraffin block using a manual arrayer (MTA-1, Beecher Instruments, Sun Prairie, WI, USA). Representative cores from normal (colon, tonsil, placenta, kidney, thyroid, breast, and prostate) and cancerous tissues (melanoma, testicular seminoma, colon carcinoma, squamous head and neck carcinoma, and endometrial carcinoma) were also loaded on the TMA block, serving as positive and negative assay controls.

Chromogenic in situ hybridization
---------------------------------

In order to detect latent EBV infection \[[@B6]\], CISH assays were performed on serial 4 μm-thick sections from the original blocks and the TMA block, using a Bond Max™ autostainer (Leica Microsystems, Wetzlar, Germany), according to the provider's specifications as described in detail elsewhere \[[@B5]\]. The poly-A probe, used as an indicator of the preservation of mRNA in the cells (positive control), resulted mainly in dark brown nuclear staining and less in a cytoplasmic one.

Immunohistochemistry -- selection of proteins
---------------------------------------------

Immunohistochemical labelling was performed on serial 3 μm-thick sections from the original blocks and the TMA block. Proteins involved in angiogenesis, cell adhesion, assembly, proliferation and differentiation, cell cycle and transcription regulation, DNA repair, microtubule assembly, and inflammation mediation were investigated. A list of the studied proteins, the sources of antigens and the staining procedures for IHC and the cut-offs used \[[@B6]-[@B11]\] are quoted in Table [1](#T1){ref-type="table"}. The Multi-Cytokeratin (AE1/AE3) was used as a control stain for the identification of tumor cells.

###### 

Studied proteins, primary antibodies, source and dilutions of antibodies, staining patterns, and interpretation (cut-off) criteria used in the present study

  **Protein**                                **Antibody \[clone, source\]**   **Antibody dilution**   **Time/Pretreatment**   **Incubation Time**   **Cutoff (%)**   **Staining pattern**
  ------------------------------------------ -------------------------------- ----------------------- ----------------------- --------------------- ---------------- ----------------------
  *Cell adhesion molecules*                                                                                                                                           
    E-cadherin                               HECD-1^1^                        1:30                    20 min / ER1            60 min                IRS ≥5           C, C/M
    P-cadherin                               56^2^                            1:200                   20 min / ER2            O/N                   IRS ≥5           C, C/M
  *Cell assembly molecules*                                                                                                                                           
    Fascin-1                                 IM20^1^                          1:400                   20 min / ER1            O/N                   5%               C
    Cytokeratin Multi                        AE1/AE3^1^                       1:100                   10 min / Enzyme 1       20 min                1%               C
  *Cell cycle regulators*                                                                                                                                             
    Cyclin D1                                SP4^3^                           1:80                    20 min / ER1            30 min                IA (5%)          N
  *Cell growth molecules*                                                                                                                                             
    VEGF-A                                   VG1^4^                           1:75                    20 min / ER2            60 min                5%               C
    VEGF-C                                   18-2255, pl^5^                   1:250                   20 min / ER1            O/N                   5%               C
    Phospho-mTOR^Ser2448^                    49 F9^6^                         1:30                    20 min / ER1            20 min                5%               C, C/PN
  *Cell proliferation molecules*                                                                                                                                      
    Ki67                                     MIB1^4^                          1:70                    15 min / ER2            20 min                IA (13%)         N
  *Cell receptors*                                                                                                                                                    
    EGFR                                     31 G7^5^                         1:50                    8 min / Enzyme 2        20 min                10%              M, C/M
    VEGFR-2                                  55B11^6^                         1:450                   20 min / ER2            O/N                   5%               C, C/N
    VEGFR-3                                  KLT9^1^                          1:50                    15 min / ER1            O/N                   5%               C
  *DNA repair molecules*                                                                                                                                              
    ERCC1                                    8 F1^2^                          1:300                   15 min / ER2            30 min                50%              N, C/N
    p53                                      DO-7^4^                          1:100                   20 min / ER1            20 min                50%              N, N/C
  *Inflammation mediators*                                                                                                                                            
    COX-2                                    4H12^1^                          1:300                   20 min / ER1            O/N                   IRS≥3            C
  *Microtubule assembly*                                                                                                                                              
    MAPT (Tau)                               2B2.100^7^                       1:100                   20 min / ER1            O/N                   5%               C, N, C/N
  *Molecules with kinase activity*                                                                                                                                    
    Phospho-AKT^Ser473^                      D9E^6^                           1:150                   20 min / ER2            O/N                   5%               C, N, C/N
    Phospho-GSK-3β^Ser9^                     5B3^6^                           1:50                    20 min / ER1            O/N                   5%               C, N, C/N
    Phospho-p44/42 MAPK^Thr202/Tyr204^       20 G11^6^                        1:1000                  20 min/ ER1             O/N                   5%               C, N, C/N
  *Transcriptional activator or repressor*                                                                                                                            
    p63                                      4A4^1^                           1:50                    20 min / ER2            60 min                5%               N
  *Tumor suppressor*                                                                                                                                                  
    PTEN                                     6H2.1^4^                         1:300                   20 min / ER2            60 min                10%              C, N, C/N

^1^Leica Biosystems, Newcastle, UK; ^2^Thermo Fisher Scientific, Fremont, CA;^3^Spring Bioscience, Pleasanton, CA; ^4^Dako, Glostrup, Denmark; ^5^Invitrogen, Carlsbad, CA; ^6^CST: Cell Signaling Technology, Danvers, MA; ^7^United States Biological, Swampscott, MA.

ER1: Epitope Retrieval 1 (citric acid, pH 6); ER2: EDTA (pH 8.8); IA: image analysis; IRS: immunoreactive score=Intensity (0--3) +% of stained cells (0:0-5%, 1:6-25%, 2:26-50%, 3:\>50%); min: minutes; M: membrane; N: nuclear; O/N: overnight; pl: polyclonal; PN: perinuclear; C: cytoplasm; C/M: cytoplasm/membrane.

Evaluation of the CISH and IHC
------------------------------

The evaluation of CISH and IHC stained sections was done simultaneously by two pathologists (G.K. and M.B.) blinded as to the patients' clinical characteristics and survival data, according to the criteria quoted in Table [1](#T1){ref-type="table"}. Tumor cells containing EBER transcripts were evaluated as positive when an intense, brown, predominantly nuclear staining was present in \>1% of tumor cells \[[@B12]\]. Only poly-A probe positive cases were evaluable for EBER status. IHC cut-off values were defined prospectively, based on distributional analyses in frequency histograms and the medical literature. In order not to miss cut-off values with prognostic utility, a Receiver-Operating Curve analysis of IHC staining scores was followed with disease progression as the indicator parameter; this analysis failed to show any cut-off with significant sensitivity and specificity (Table [1](#T1){ref-type="table"}). Based on the selected IHC cut-offs, protein expression status was defined for each tumor as either negative or positive, except for Ki67 which was graded as low (≤13%) or high (\>13%). Representative cases of CISH and IHC staining are presented in Additional file [1](#S1){ref-type="supplementary-material"}: Figure S1.

Image analysis
--------------

Stained sections for Cyclin D1 and Ki67 were evaluated using an image analysis system as described \[[@B5]\]. The cut-offs used for the evaluation of Cyclin D1 and Ki67 staining are quoted in Table [1](#T1){ref-type="table"}.

Statistical analysis
--------------------

Categorical data are displayed as frequencies and corresponding percentages, while continuous data by median and range. For the comparison of continuous data the non-parametric Kruskall Wallis test was used, while the comparison of categorical data between groups was performed by Fisher's exact or Pearson chi-square tests, where appropriate. Overall survival (OS) was measured from the date of treatment randomization to patient's death or last contact. Progression-free survival (PFS) was measured from the date of treatment randomization to documented disease progression, death without prior documented progression or last contact. Time-to-event distributions were presented using Kaplan-Meier curves and compared using the log-rank test. Unsupervised hierarchical clustering analysis using the majority of the examined biomarkers was conducted. Univariate Cox regression analyses were performed for OS and PFS, to assess the prognostic or predictive significance of biomarkers adjusted for treatment. A backward selection procedure with a removal criterion of p\>0.10 was performed in the multivariate Cox regression analysis in order to identify significant factors among examined biomarkers, basic clinicopathological characteristics (categorized as given in Additional file [2](#S2){ref-type="supplementary-material"}: Table S1) and treatment group. For all comparisons the level of significance was set at α=0.05. All results are presented according to reporting recommendations for tumor marker prognostic studies \[[@B13]\]. Analyses were performed with the use of the SPSS v. 17.0 (SPSS, Inc., Chicago, IL), JMP version 8 and SAS version 9.3 (SAS, Institute Inc., Cary, NC, USA).

Results
=======

Patient and tumor characteristics -- survival times
---------------------------------------------------

Selected patient and tumor characteristics are quoted in Table [2](#T2){ref-type="table"}. The male/female ratio was 2.24/1. The majority of patients were of PS 1 or 2, early T stage and advanced lymphnode involvement. Findings deserving closer attention are the normal pattern of age distribution (Figure [2](#F2){ref-type="fig"}) and the relatively low incidence of WHO Type I disease, given that the population was Caucasian (9.3%).

###### 

Patient demographics and disease characteristics

  **Age (years)**                                            
  ------------------------ ------------- ------------- ---- ----
    Median (range)         49 (15--82)                      
  **Gender**               **N**         **%**               
    Men                    74            69.2                
    Women                  33            30.8                
  **Performance status**                                     
    0                      38            35.5                
    1-2                    69            64.5                
  **T classification**                                       
    T1                     23            21.5                
    T2                     40            37.4                
    T3                     16            14.9                
    T4                     28            26.2                
    T1+T2                  63            58.9                
    T3+T4                  44            41.1                
  **N classification**                                       
    N0                     15            14.0                
    N1                     27            25.2                
    N2                     44            41.1                
    N3a                    4             3.7                 
    N3b                    17            15.9                
    N0+N1                  42            39.3                
    N2+N3                  65            60.7                
  **Clinical stage**                                         
    II-III                 64            59.8                
    IV                     43            40.2                
  **WHO classification**                                     
    Type I                 10            9.3                 
    Type II                21            19.6                
    Type III               76            71.0                
  **History of smoking**                                     
    No                     71            66.4                
    Yes                    36            33.6                
  **Alcohol abuse**                                          
    No                     100           93.5                
    Yes                    7             6.5                 
  **Hemoglobin level**                                       
    ≥12                    10            9.3                 
    \<12                   94            87.9                
    Unknown                3             2.8                 
  **Best Response**        **Group A**   **Group B**        
    CR                     42            58            38   55
    PR                     18            25            21   30
    ORR                    60            83            59   85
    SD                     3             4             2    3
    PD                     2             3             5    7
    NE                     7             10            3    4

CR: complete response; PR: partial response; ORR: overall response rate; SD: stable disease; PD: progressive disease; NE: not evaluated.

![Age distribution frequencies of the studied nasopharyngeal patient population.](1472-6890-13-1-2){#F2}

The patients have been followed for an additional period of 21.8 months compared to the respective clinical study \[[@B5]\]. After a median follow-up time of 76.8 months (range 42.3-99.2 months), 3-year PFS and OS rate for all patients in the study were 60.7% and 66.4%, respectively. Mean PFS and OS for all patients were 49.7 months and 52.9 months, respectively. No statistically significant differences emerged when time-to-event times were analyzed with respect to the treatment group (mean PFS: 51.1 months for Group A vs. 47.4 months for Group B, p = 0.65; mean OS: 53.4 months for Group A vs. 51.7 months for Group B, p = 0.938).

Frequency of IHC marker expression
----------------------------------

Biomarkers with the most frequent expression (\>90% positive cases) were: p53, COX-2, P-cadherin, EBER, phospho-GSK-3β (p-GSK-3β), and Fascin-1. On the contrary, the least IHC-expressed proteins (\<50% positive cases) were as follows: VEGFR-2, phospho-mTOR^Ser2448^ (p-mTOR), VEGF-A, and p16 (Table [3](#T3){ref-type="table"}).

###### 

Frequency of immunohistochemical expression of the examined biomarkers in nasopharyngeal carcinoma (sorted from the most frequently expressed to the least frequently ones)

  **Biomarker**                        **No of Cases**   **Positive (%)**   **Negative (%)**
  ------------------------------------ ----------------- ------------------ ------------------
  Multi-Cytokeratin                    103               102 (99)           1 (1)
  COX-2                                94                90 (95.7)          4 (4.3)
  P-cadherin                           97                92 (94.8)          5 (5.2)
  EBER                                 101               94 (93.1)          7 (6.9)
  Phospho-GSK-3β^Ser9^                 100               92 (92)            8 (8)
  Fascin-1                             96                88 (91.7)          8 (8.3)
  E-cadherin                           94                83 (88.3)          11 (11.7)
  p63                                  94                83 (88.3)          11 (11.7)
  EGFR                                 95                83 (87.4)          12 (12.6)
  p53                                  95                82 (86.3)          13 (13.7)
  Phospho-AKT^Ser473^                  96                79 (82.3)          17 (17.7)
  Ki67                                 100               78 (78)            22 (22)
  ERCC1                                105               78 (74.3)          27 (25.7)
  MAPT (Tau)                           104               74 (71.2)          30 (28.8)
  VEGF-C                               100               64 (64)            36 (36)
  Phospho-p44/42 MAPK^Thr202/Tyr204^   95                60 (63.2)          35 (36.8)
  PTEN                                 102               64 (62.7)          38 (37.3)
  VEGFR-3                              101               60 (59.4)          41 (40.6)
  Cyclin D1                            102               53 (52)            49 (48)
  VEGFR-2                              95                44 (46.3)          51 (53.7)
  Phospho-mTOR^Ser2448^                101               38 (37.6)          63 (62.4)
  VEGF-A                               100               36 (36)            64 (64)
  p16                                  105               5 (4.8)            100 (95.2)

Association of protein expression with clinicopathological characteristics and response to treatment
----------------------------------------------------------------------------------------------------

The statistically significant correlations of patients' clinicopathological characteristics with the IHC proteins expression are presented in Additional file [2](#S2){ref-type="supplementary-material"}: Table S1. Notably, PTEN and p63 expression patterns were clearly linked with favorable characteristics: patient PS and T stage (for the former), T and AJCC TNM stage (for the latter). Positive phospho-AKT (p-AKT) and phospho-p44/42MAPK (p-MAPK) expression were related to male gender, positive p-GSK-3β and ERCC1 expression depicted a more advanced age at diagnosis, and deficiency of ERCC1 and p-mTOR expression were correlated to poor patient PS. As expected, positive EBER expression status was linked to WHO Type III histology. Unexpectedly, Ki67-positive tumors were more frequently associated with earlier N stage and good PS; likewise, Cyclin D1 expression was more often positive in tumors of earlier AJCC TNM stage.

Associations between the expression status of the tested biomarkers and response to treatment did not reveal significant predictive values for any of them (Data not shown).

Paired associations of protein expression as detected by IHC
------------------------------------------------------------

Additional file [3](#S3){ref-type="supplementary-material"}: Table S2 presents all statistically significant paired associations of protein IHC expression. The most interesting paired interactions were as follows: p63/p-AKT, p63/Ki67, p-AKT/Ki67, p-AKT/ERCC1, Ki67/ERCC1, Ki67/PTEN, Ki67/Cyclin D1, p-mTOR/ERCC1, and p-mTOR/VEGFR3.

Consequently, the most informative biomarkers in NPC with regards to IHC expression were: p63, p-AKT, Ki67, ERCC1, CyclinD1, p53, COX-2, and p-mTOR.

Profiling cluster models of protein expression
----------------------------------------------

In an effort to study the complex interactions among the examined biomarkers, cluster analysis of the IHC protein expression was performed.

Firstly, all protein targets were included in the analysis and gradually increasing numbers of clusters were tested for their prognostic significance with respect to PFS and OS as well as their association with T and N status, AJCC TNM stage, and overall response rate (ORR) to treatment. The only model with prognostic significance was a 2-cluster one, with a borderline association to favorable OS (p=0.048) (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}) and earlier TNM stage (p=0.027 for stage IIB-III vs. IV). Cluster analysis for each of the two treatment groups (A and B) did not result in the emergence of any meaningful prognostic significance.

![**Hierarchical clustering analysis of the studied biomolecules in nasopharyngeal carcinoma.** Red and green signals indicate cases with increased and decreased protein expression, respectively; white signals indicate missing cases. Two clusters are distinguished, red and green, with different predominant patterns of protein expression.](1472-6890-13-1-3){#F3}

![Prognostic significance for overall survival of the red and green clusters, with predominantly increased and decreased protein expression, respectively.](1472-6890-13-1-4){#F4}

A following step was to look at a more compact set of protein targets (such as p-AKT, p-mTOR, PTEN, VEGF-A, ERCC1, and p53) based on their relative significance in driving carcinogenesis or their possible synergistic action. In this case, no cluster appeared to confer prognostic information for any of the endpoints tested.

Univariate analysis
-------------------

In univariate Cox regression analysis adjusted for treatment, the only biomarkers with positive prognostic value were EBER and p63, the latter being important also in the premature translational analysis of the relevant clinical study \[[@B7]\]. Particularly, EBER expression was linked to a favorable OS in a statistically significant way (hazard ratio HR = 0.38, 95% CI = 0.15-0.99, p = 0.048), while its association to improved PFS was only of borderline significance (HR = 0.44, 95% CI = 0.17-1.14, p = 0.09). The favorable prognostic value of positive p63 expression was borderline only for OS (HR = 0.48, 95% CI = 0.21-1.09, p=0.08) (Table [4](#T4){ref-type="table"} and Additional file [4](#S4){ref-type="supplementary-material"}: Figures S2).

###### 

Univariate Cox regression analysis for the examined biomarkers adjusted for treatment

                          **OS**   **PFS**                                    
  ----------------------- -------- ----------- ----------- ------ ----------- -----------
  **EBER**                                                                     
    Negative              1                                1                   
    Positive              0.38     0.15-0.99   **0.048**   0.44   0.17-1.14   **0.09**
  **p63**                                                                      
    Negative              1                                1                   
    Positive              0.48     0.21-1.09   **0.08**    0.56   0.25-1.28   0.17
  **Cyclin D1**                                                                
    Negative                                                                   
    Group B vs. Group A   0.44     0.18-1.04   **0.062**   0.5    0.22-1.16   0.11
    Positive                                                                   
    Group B vs. Group A   2.02     0.81-5.07   0.13        2.64   1.08-6.48   **0.034**

Of special interest was the predictive significance of Cyclin D1 expression, which emerged only when the patient population was adjusted for the administered treatment (Group A vs. Group B). In this case, immunopositivity for Cyclin D1 resulted in a statistically significant worse prognosis in terms of PFS for patients in Group B (HR = 2.64, 95% CI = 1.08-6.48, p=0.034) (Table [4](#T4){ref-type="table"}), while the absence of Cyclin D1 expression conferred a trend of better OS for the same Group (HR = 0.44, 95% CI = 0.18-1.04, p=0.062) (Table [4](#T4){ref-type="table"}). Log-Rank test was subsequently performed, which confirmed the results of Cox regression analysis mentioned above (Figures [5](#F5){ref-type="fig"}A and [5](#F5){ref-type="fig"}B).

![**Prognostic significance of Cyclin D1 expression.** Log-Rank test for the effect of Cyclin D1 expression on progression-free and overall survival, stratified by treatment group (Group A: patients treated with induction chemotherapy followed by concurrent chemo-radiotherapy; Group B: patients treated with concurrent chemo-radiotherapy only); (**A**) positive and (**B**) negative Cyclin D1 expression.](1472-6890-13-1-5){#F5}

Multivariate analysis
---------------------

The following parameters were pointed out by multivariate analysis as the significant prognostic indicators for both PFS and OS: age at diagnosis, treatment group, PS, AJCC TNM stage, p-mTOR and ERCC1 expression. Notably, not only the same variables were indicated as important for both PFS and OS, but also the magnitude of significance (denoted by HR value) was similar in both conditions (Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}).

###### 

Multivariate Cox model for progression-free survival

                            **Parameter Estimate**   **Standard Error**   **p-value**   **HR**   **95% CI**
  ------------------------- ------------------------ -------------------- ------------- -------- -------------
  **Age**                   0.042                    0.011                \<0.001       1.043    1.020-1.065
  **Group**                                                                                       
    Group B vs. Group A     0.41                     0.33                 0.21          1.5      0.89-2.84
  **PS**                                                                                          
    1-2 vs. 0               1.5                      0.41                 \<0.001       4.47     1.98-10.01
  **Stage**                                                                                       
    IV vs. II-III           0.95                     0.33                 0.005         2.58     1.34-4.96
  **p-mTOR**                                                                                      
    Positive vs. Negative   −0.8                     0.33                 0.031         0.45     0.22-0.93
  **ERCC1**                                                                                       
    Positive vs. Negative   1.02                     0.41                 0.013         2.79     1.24-6.29

###### 

Multivariate Cox model for overall survival

                            **Parameter Estimate**   **Standard Error**   **p-value**   **HR**   **95% CI**
  ------------------------- ------------------------ -------------------- ------------- -------- -------------
  **Age**                   0.047                    0.011                \<0.001       1.048    1.024-1.073
  **Group**                                                                                       
    Group B vs. Group A     0.23                     0.33                 0.5           1.25     0.66-2.40
  **PS**                                                                                          
    1-2 vs. 0               1.4                      0.42                 \<0.001       4.06     1.79-9.19
  **Stage**                                                                                       
    IV vs. II-III           0.92                     0.34                 0.007         2.5      1.28-4.89
  **p-mTOR**                                                                                      
    Positive vs. Negative   −0.76                    0.38                 0.044         0.47     0.22-0.98
  **ERCC1**                                                                                       
    Positive vs. Negative   0.93                     0.42                 0.028         2.54     1.11-5.81

Particularly, advanced age, the addition of induction chemotherapy, poor PS, AJCC stage IV, and positive ERCC1 expression were associated with a higher probability of disease progression and death. On the contrary, positive p-mTOR expression was related to a decreased risk of progression and death (Additional file [4](#S4){ref-type="supplementary-material"}: Figures S2).

Compared to the preliminary analyses performed in the context of the respective clinical study \[[@B7]\], Ki67 and p63 lost their independent prognostic value in the longer follow-up, in contrast to age, PS, and AJCC TNM stage which maintained their significance.

Discussion
==========

In contrast to the progress seen in the molecular classification, pathogenesis elucidation and management of quite a few neoplasms, little has been achieved towards personalized approach in the NPC field so far. In contrast to the paradigm of other neoplasms, no activating mutations, such as EGFR or PI3K, are known to drive nasopharyngeal carcinogenesis \[[@B14],[@B15]\]. It seems that nasopharyngeal carcinogenesis is far more composite than the almost ubiquitous EBV presence depicts. As a result, survival rates of patients with advanced disease remain poor, especially for non-endemic populations \[[@B16]\]. During the last few years, we have witnessed combined efforts to unravel NPC pathogenesis by utilization of multiple gene expression profile datasets, definition of novel gene signatures and molecular or cytokine markers, integration of miRNA technologies, and exploration of epigenetics.

The present study incorporates novel features which differentiate it from the rest utilizing IHC in NPC. In particular, 21 protein targets have been simultaneously profiled for their expression levels in nasopharyngeal tumors, in order to observe possible cross-talks between pathways. Biomarkers were carefully chosen, in order to include representatives from as many as possible oncogenic processes, as reviewed recently \[[@B17]\]. In view of this, the clustering analysis performed is considered even more informative. More importantly, the study population was a Caucasian one, representing not only the entire Greek region but also the Balkan Peninsula, since HECOG-affiliated hospitals from both Greece and Romania have participated in this study. Although a considerable number of Caucasian NPC patients have been studied during the last decades \[[@B18]-[@B23]\], the respective series have either focused just on clinical parameters or have investigated only a limited number of biomarkers.

The high frequency of EBER CISH expression was not surprising, even for the Caucasian population of our study, as EBV infection is almost ubiquitous globally and plays a major role in the pathogenesis of NPC in both endemic and non-endemic areas \[[@B1]\]. Generally, our study confirmed that the well-established characteristics of EBV-related NPC are also applicable to Caucasian NPC patients. Namely, the strong connection of EBV to WHO Type II and III histology as well as to the more favorable disease course \[[@B24]\]. Importantly, the univariate analysis indicated EBER expression as a significant prognostic factor of improved OS.

Cyclin D1 is one of the key proteins involved in cell cycle control, a process considered as critical in the development of NPC \[[@B25]\]. Although our study did not find as high uniform Cyclin D1 expression as reported in the literature \[[@B7]\], IHC expression levels were interestingly informative. Firstly, a statistically significant association between Cyclin D1 and Ki67 as well as between Cyclin D1 and p-AKT expression was indicated, pointing to an active cell proliferation axis, which has already been investigated as a therapeutic target in NPC \[[@B26]\]. More importantly, univariate analysis pointed to a predictive role for Cyclin D1 protein levels, as differences in PFS and OS emerged only when the study population was adjusted for treatment. In particular, patients treated with induction chemotherapy prior to chemo-radiotherapy fared significantly better (in terms of PFS) in the case of positive Cyclin D1 expression, while in the absence of Cyclin D1 this finding was inverted (for OS). Consequently, it seems that tumors with enhanced Cyclin D1 function are vulnerable to more aggressive treatment. This result is in fine agreement with the reported radio-sensitivity of Cyclin-enriched nasopharyngeal \[[@B7]\], laryngeal \[[@B27]\], and breast \[[@B28]\] cancers.

The function of p63, a transcription factor and member of the p53 family, is rather complicated in NPC, since two major classes of p63 isoforms have been identified: the full-length TAp63 and the N-terminal truncated ΔNp63 \[[@B29]\]. The two isoforms exert opposite purposes; TAp63 isoform has similar function to the wild-type p53 protein, while ΔNp63 is thought to antagonize TAp63 and p53 in target gene regulation. Each isoform can be targeted by a specific antibody for IHC evaluation, while a pan-p63 one binds to common epitopes. Consequently, reports of overexpression and oncogenic properties of p63 in NPC \[[@B30],[@B31]\] should be construed through this prism, also bearing in mind that the predominant isoform is the truncated ΔNp63 one. In our study, a pan-p63 antibody was utilized, thus limiting the importance of the borderline favorable prognostic value for OS, which emerged for p63 in the univariate analysis. Accordingly, the strong correlation of p63 expression with p-AKT and Ki67 as well as its association with early disease stage should be interpreted with caution.

The virtual absence of p16 IHC expression in our study (only 5% positive tumors) has been constitutively documented in nasopharyngeal cancers \[[@B32]\], attributable mainly to aberrant methylation or even to gene deletion. In contrast to reports supporting a predictive role of p16 to both chemotherapy (5-flouoruracil and cisplatin) \[[@B33]\] and radiotherapy \[[@B34]\], our study did not find any connection of p16 protein expression with disease outcome. Likewise, despite the documented unfavorable value of p16 expression in NPC \[[@B7],[@B35]\], such a role did not emerge in our study. The inevitable small number of p16-positive cases undoubtedly calls for a cautious reading of these results.

Activation of the PI3K/AKT/mTOR pathway has been reported in NPC several years ago \[[@B36]\]. AKT phosphorylation can be either a result of LMP1 \[[@B37]\] or EGFR \[[@B14]\] action on PI3K or a compensatory consequence of decreased PTEN levels \[[@B38]\]. However, EBER/p-AKT or EGFR/p-AKT protein interactions did not emerge in our study. Moreover, the comparable expression levels of p-AKT and PTEN argue in favor of a downward activation of AKT instead of a compensatory one. p-AKT association with the Ki67 status may reflect the known propensity of AKT-activated NPC to metastasize \[[@B39]\]; however, we could not confirm the contribution of decreased E-cadherin levels to this phenomenon \[[@B40]\].

Cadherin IHC expression did not acquire any significance in our study with regard to disease prognosis or association with the rest biomolecules examined. Despite the reported depletion of E-Cadherin expression in NPC tissues in comparison to the normal ones \[[@B32],[@B41]\], a high level of IHC expression was observed in our study, both for P- and for E-Cadherin. One possible explanation is the low IHC cut-off that was selected, compared to other reports \[[@B42]\]. On the other hand, the enhanced Cadherin expression might not merely be an artifact but could reflect a lack of its contribution to NPC pathogenesis in Caucasian patients. Such a scenario would justify the absence of any unfavorable prognostic value, contrary to reports of low tumor Cadherin levels in NPC patients with advanced disease stage and decreased survival \[[@B43]\].

The predictive role of high ERRC1 protein levels to cisplatin-containing regimens has been firstly described in ovarian cancer 20 years ago \[[@B44]\]. However, it was only recently that similar reports were published in NPC \[[@B45]\]. In line with this evidence, multivariate analysis in our study showed a significant unfavorable association of increased ERCC1 expression with both PFS and OS. Since cisplatin was the chemotherapy backbone in both patient groups, this outcome could be explained as a negative predictive effect of high ERCC1 protein levels. In addition, a poor prognostic value of ERCC1 could also be contemplated, as increased ERCC1 protein levels were significantly associated with aggressive disease characteristics, such as positive Ki67 and p-AKT IHC expression.

Loss of PTEN expression is a frequent event in NPC \[[@B46]\], accounting for the extensive deregulation of cellular signaling pathways (e.g. PI3K/AKT/mTOR and Wnt) and the metastatic propensity via induction of the epithelial-mesenchymal transition phenotype. Our study, in line with the literature evidence, has found a relatively low rate of PTEN expression. Moreover, PTEN presence was significantly associated with early tumor stage, a finding which has been also described in Chinese NPC patients \[[@B47]\].

Increased COX-2 IHC expression in NPC has been linked to the presence of lymph node metastasis \[[@B48]\] and worse survival, as well to enhanced sensitivity to the radiotherapy effects \[[@B49]\]. In contrast to such well-established evidence, no prognostic or predictive role for COX-2 was revealed in our study, despite the higher COX-2 expression frequency compared to previous reports \[[@B50]\]. However, in line with our observations are a few studies \[[@B51]\] which indicate no prognostic significance of COX-2 or even a positive one \[[@B52]\], thus perplexing COX-2 contribution to NPC pathogenesis. Commonly reported co-expression patterns, such as COX-2/EGFR/VEGF \[[@B53]\], COX-2/EGFR \[[@B54]\], and COX-2/LMP1 \[[@B55]\] were not confirmed in the present study. The axis LMP1/COX-2/VEGF \[[@B56]\], in which COX-2 is promoted by LMP1 and subsequently induces VEGF, was also not manifested in our Caucasian patient series.

However extensive our investigation was, a bunch of biomolecules and processes were not shown to contribute in any way to NPC pathogenesis, despite the strong literature evidence to the contrary. In particular, p-MAPK was neither evident in our tumor series nor was clinically significant, counter to reports of an activated and tumor-promoting MAPK in NPC \[[@B57]\]. Likewise, despite p-GSK-3β being reported as a vital member of the PI3K/AKT/GSK-3β/Cyclin D1 pathway in NPC promotion \[[@B26],[@B36],[@B46]\], the present study did not result in such evidence. Similarly, p53 expression was not informative in terms of disease prognosis or interaction with any other biomarker. Several reports state the overexpression or accumulation of p53 protein in the vast majority of NPC \[[@B58]\] and a resulting tumor-promoting role ; however, p53 expression was not detected to that extent in our study. Anyway, the functional status of p53 is disputable in NPC \[[@B59]\], which could explain the absence of its prognostic value \[[@B59]\], as indicated also in our study. The antagonizing effect of ΔNp63 protein on p53, as quoted above, renders the conclusion-making procedure even more insecure. Fascin, an actin cross-linking protein, has been implicated in the progression of various neoplasms, including NPC, mainly through the promotion of cell migration and adhesion \[[@B60]\]. In spite of Fascin's high expression frequency in our study, any significant correlation of Fascin-1 to NPC pathogenesis cannot be implied.

The absence of any prognostic role for EGFR in our Caucasian population, despite its high expression frequency, is a result which needs particular consideration. There is a substantial bulk of evidence concerning the unfavorable prognostic value of EGFR both for disease stage and for outcome \[[@B61]\], even in Caucasian populations \[[@B62]\], the only exception being a recent Korean study \[[@B51]\]. Additionally, several co-expression patterns have been described, such as EGFR/COX-2 \[[@B53],[@B54]\], EGFR/VEGF \[[@B53]\], and EGFR/AKT \[[@B14]\], not being manifested in our series. Although EBV presence is believed to induce EGFR \[[@B63]\], such a paired expression model was also not found. The paucity of EGFR-expression information in the present study could be interpreted in the context of the evolving understanding of EGFR role in NPC pathogenesis; EGFR downstream signaling molecules are numerous in NPC and are still being defined \[[@B64]\]. The relative inefficacy of EGFR-targeting attempts in NPC \[[@B65]\], in contrast to HNSCC \[[@B66]\], serves as a reminder of the underlying complexity.

VEGF-A and -C expression status were also not informative with regard to prognosis or any association with clinicopathological variables. In spite of the abundant literature references of an adverse prognostic role of VEGF expression in NPC \[[@B67],[@B68]\] and VEGF-C in particular \[[@B69]\], no such effect was shown. Furthermore, several co-expression pairs have been repeatedly described, mainly between VEGF, COX-2, EGFR, and LMP1 \[[@B56],[@B70]\], which were not prominent in our tumor series. Anyway, the exact setting in which angiogenesis exerts its tumor-promoting action needs to be clarified, as depicted by the modest results of anti-angiogenic therapy so far \[[@B71]\].

Phosphorylated-mTOR expression emerged as an independent favorable prognostic factor in multivariate analysis, although with borderline significance. mTOR is linked with a promoting role in nasopharyngeal carcinogenesis \[[@B72]\] and a unanimous adverse prognostic value in NPC \[[@B73]\], which is alleviated by mTOR inhibition \[[@B38]\]; thus, the aforementioned result is considered as unexpected. Possible hypotheses for this discrepancy are: a) the presence of p53 expression in all p-mTOR tumors could account for a favorable outcome upon treatment and b) multiple comparisons in a sample underpowered for such exhausting statistical analyses could lead to an artifact. Similarly, the association of increased Ki67 with an earlier N stage and good PS is rather surprising and could be attributed either to a statistical artifact, as mentioned above, or to the IHC cut-off level which have been used.

Clustering analysis did not reveal any discriminator group of genes/biomolecules which could portray a specific driving scenario of carcinogenesis in NPC. Moreover, no NPC subtype emerged on the basis of differential protein expression, which could point towards potential therapeutic targets. Following the breast cancer paradigm \[[@B74]\], the reported gene-profiling approaches in NPC end up to different gene sets \[[@B75],[@B76]\], calling once again for the need of bioinformatics implementation to data interpretation.

It should be noted that the reported high frequency of WHO Type I NPC histology in Caucasian populations (approximately 25%) \[[@B2]\] was not represented in our study (only 9%). Possibly, Balkan NPC patients represent an intermediate population in terms of epidemiology, as Balkan Peninsula shares the Mediterranean Basin and neighbors to North Africa, which is a known endemic NPC area.

The results of the present study should be interpreted on the notion of the inherent limitations of IHC. Protein expression levels often mirror the mechanisms leading to cellular growth deregulation; however, they have to be translated along with the coexisting genetic and epigenetic alterations. Moreover, clustering analysis is unable to provide a perfect outline of the complex interactions between the tumor-promoting networks; small-size samples and multiple comparisons undermine the validity of the results. Last but not least, since several phospho-antibodies were utilized, consideration should be paid to the disputable reliability of FFPE IHC for phosphorylated epitopes \[[@B77]\].

Conclusions
===========

Despite the existence of published evidence to the contrary, the extensive IHC study and profiling of a broad variety of biomolecules did not result in tangible conclusions for many of them. However, our study came to conclusions which could represent a step forward in disclosing the pathogenesis of NPC in Caucasian populations. The favorable prognostic value of EBER and p63, the treatment-dependent prognostic significance of Cyclin D1, as well as the independent prognostic value of ERCC1 and p-mTOR protein levels could be pointed as the most interesting ones. What lies ahead is the prospective validation of these biomarkers and, hopefully, a meaningful benefit for NPC patients.
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###### Additional file 1

**Figure S1.** Protein expression detected by IHC and CISH in tissue microarrays from nasopharyngeal carcinoma cases. (**a**) p53; (**b**) EGFR; (**c**) COX-2; (**d**) VEGF-A; (**e**) MAPT; (**f**) E-cadherin; (**g**) PTEN; (**h**) p-GSK-3β; (**i**) VEGF-C; (**j**) ERCC1; (**k**) Fascin-1; (**l**) p-AKT; (**m**) p-p44/42 MAPK; (**n**) VEGFR-2; (**o**) Cyclin D1; (**p**) P-cadherin; (**q**) p-mTOR; (**r**) p63; (**s**) VEGFR-3; (**t**) Ki67; (**u**) Multi-Cytokeratin; (**v**) mRNA probe (CISH); (**w**) EBER probe (CISH). Original magnification ×100.
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###### Additional file 2

**Table S1.** Statistical correlations of biomolecules expression with clinicopathological parameters.

###### 

Click here for file

###### Additional file 3

**Table S2.** Paired associations of protein expression (Fisher's exact test).

###### 

Click here for file

###### Additional file 4

**Figure S2.** Prognostic significance of EBER, p63, mTOR, ERCC1 and Cyclin D1 protein expression for progression-free and overall survival (Log-Rank test). For Cyclin D1, all patients have been included, irrespective of the treatment administered.
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